KRAS and non-small cell lung carcinoma: Although XMU‐MP‐5 was effective against H3122 cells, it showed negligible activity in ALK‐negative NSCLC cell lines, including A549 (KRAS mutant), H1299 (EGFR wild‐type), and PC9 (EGFR exon 19 deletion) (Appendix Fig S3B and C).